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Abstract 
Activation of GPR4 by acidosis inhibits tumor cell migration, invasion and metastasis.  
Reid David Castellone.  (Under direction of Dr. Li Yang)  Department of Biology.  April 
2011.  
 
Melanoma and Prostate Cancer are two of the most diagnosed forms of cancer in the 
United States.  The ability to metastasize and colonize in a distant location is one of the 
most devastating hallmarks of cancer as modes of treatment are severely limited and 
often inefficient.  As cancer accounts for one out of every four deaths in the United 
States, there is no doubt as to the necessity to develop novel strategies to combat cancer 
progression.  Cancer research has transformed to not only target the actual tumor cells, 
but also the tumor microenvironment as it is known to play a strong role in tumorigenesis 
and cancer progression.  The defining characteristics of the tumor microenvironment are 
hypoxia, acidosis and high interstitial fluid pressure, and these characteristics actively 
select for resistant tumor cells, conferring a progressive phenotype.  GPR4, a G-protein 
coupled receptor, has recently been shown to act as a proton sensor, and as acidosis is a 
defining characteristic of the tumor microenvironment and GPR4 expression is detected 
in a wide array of human tissues, it is thought GPR4 may influence tumor cell 
progression.  Therefore, it is the purpose of this study to analyze the biological function 
acidosis activation of GPR4 has on the ability of tumor cells to acquire a motile and 
metastatic phenotype.  Through a series of cell motility, migration and invasion assays 
we have determined that GPR4 is activated by acidosis, and that this activation inhibits 
the motility, migratory and invasive ability of GPR4 overexpressing tumor cells.  
Furthermore, using a pulmonary melanoma metastasis model, we have shown that GPR4 
overexpression significantly decreases the ability for in vivo metastasis of tumor cells.  
To deduce a possible molecular mechanism by which the inhibitory phenotype is 
  
acquired, it was found that GPR4 activation increases the occurrence of actin stress fibers 
in tumor cells, indicative of upregulation of the G12/13-Rho pathway.  Furthermore, 
treatment with CN01, a known cell permeable Rho activator, significantly inhibited both 
the motility and in vivo metastasis of treated tumor cells.  In conclusion, it was found that 
GPR4 is activated by acidosis, and that this activation inhibits the ability for motility, 
migration and invasion in tumor cells.  Furthermore, GPR4 overexpression inhibits the 
ability for metastasis in a murine model, and it appears that activation of the small 
GTPase Rho is at least partially involved in the observed motility and metastasis 
inhibitory phenotypes.  
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Chapter 1:  Introduction 
Cancer Background and Statistics 
Cancer, accounting for one out of every four deaths in the United States, is one of 
the most pressing health issues under research today [1].  It is a disease generally defined 
by abnormal and uncontrolled proliferation of cells, often including the unchecked 
spreading of these tumorigenic cells to distant tissues and organs [2].  Cancer involves 
dynamic changes in the cell genome that translate into DNA mutations. These mutations 
produce oncogenes with dominant gain of function, along with a recessive loss of 
function in tumor suppressor genes [3].  These cancer initiation genetic mutations are 
caused by internal factors like random mutations of the genome, along with external 
factors such as tobacco, chemicals and radiation [4].    
Behind heart disease, cancer is the most common cause of death in the United 
States, with more than 1,500 Americans projected to have lost their lives every day in 
2010.  Furthermore, 2010 saw an estimated 1,529,560 new cancer cases diagnosed [4].  
Accounting for 52% of newly diagnosed cancers in men are cancers of the prostate, 
colorectum and lung and bronchus.  In women, cancers of the breast, colorectum, lung 
and bronchus also account for 52% of newly diagnosed cases [1].   
While cancer rates seem astonishing, there is hope for the future as current five 
year survival trends have seen an increase in survival rates: the survival rate for cancers 
diagnosed between 1996 and 2003 was 66%, up from 50% in 1975-1977 [4].  
Furthermore, there was a 1.3% per year decrease from 2000 to 2006 and a 0.5% per year 
decrease from 1998 to 2006 in male and female delay-adjusted cancer incidence rates, 
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respectively [1]. This improvement reflects a progress in the early diagnosis of cancers 
and an increase in carcinogen awareness, as well as advances in research and treatment.  
This trend is a direct result of an increased interest in the development of new research 
strategies, some of which will be discussed further on in this paper. 
While every cancer case and type presents unique qualities, there are six general, 
commonly accepted defining characteristics of cancer. These six characteristics are as 
follows: self sufficiency in growth signals, insensitivity to growth inhibitory signals, 
evasion of apoptosis, sustained angiogenesis, tissue invasion and metastasis, and limitless 
replicative potential [3].  This list takes into account the genetic mutations that result in 
the expression of dominant cancer promoting oncogenes along with the loss of function 
of tumor repressor genes.  Furthermore, this list is inclusive of a major acquired 
characteristic of cancer cells that often results in patient death; this characteristic is tissue 
invasion and metastasis and will be the focus of this paper and my research.  While this 
paper will primarily be focused on tumor cell metastasis and motility, specifically as 
dictated by precise genetic engineering and interactions with the tumor 
microenvironment, it is important to remain aware that the invasive phenotype of cancer 
is due to the combinative effect of the aforementioned six acquired capabilities. 
Melanoma and Prostate Cancer 
 There were an estimated 8,700 deaths due to melanoma in 2010, with a predicted 
68,130 new cases of melanoma diagnosed in the same year.  These estimates leave 
melanoma to currently be the fifth and seventh most diagnosed forms of cancer in men 
and women, respectively.   The five year survival rate from 1999-2005 for local 
melanoma was 91%, however upon metastasizing, this survival rate fell to 15% [4].  
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Alarmingly, upon diagnosis of the metastatic disease, the median survival period is six to 
nine months [5].  Unfortunately, the rate of development for novel therapies to combat 
this disease has not paralleled the increase in occurrence.  The primary form of therapy is 
chemotherapy with alkylating agents, which offers a low response rate of 10% [6].  
Furthermore, recent studies have indicated melanoma as a prototype of chemotherapy-
resistant tumors, further complicating the development of new combative strategies [7]. 
However, somatic oncogenic mutations to the signaling transduction molecule v-raf 
murine sarcoma viral oncogene homolog B1 (BRAF) have been identified in 70% of 
melanomas and close to one half of analyzed patients with metastatic melanoma, making 
it the most commonly mutated signal transduction pathway in melanoma [8, 9].   
Ultimately, BRAF mutations lead to increased tumor cell proliferation and survival, 
characteristics that inspire the development of strategies to combat this mutation.  
Selective BRAF inhibitors have shown very promising results in the clinical setting, with 
a large percentage (>69%) of patients with BRAF mutated metastatic melanoma showing 
tumor regression upon administration of varying BRAF inhibitors [9, 10]. 
 With an estimated 217,730 new cases having been diagnosed in 2010, coinciding 
with 32,050 deaths in the same year, prostate cancer is the most diagnosed and second 
most deadly form of cancer in men in the United States. Although from 2000 to 2006 
there was a 2.4% decrease in incidence rate per year, the incidence rate is still one of the 
highest and thus an area of concern [4].  As with most cancers, there is a high treatment 
success rate upon eradication of a localized, primary tumor.  However, 70% of patients 
with advanced prostate cancer see metastasis to the bone, with metastasis severely 
worsening the patient’s prognosis [11]. 
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 From the previously described statistical data, the widespread impact of both 
metastatic melanoma and prostate cancer is astonishing.  With melanoma being the 
seventh most diagnosed form of cancer in women,  and melanoma and prostate cancer 
being the fifth and second most diagnosed forms of cancer,  respectively, in men, it is 
clear how pressing of an issue the development of techniques to combat the spread of 
these forms of cancer is [4]. 
Transformations in Cancer Research 
 Cancer therapy is currently expanding its paradigms from targeting strictly tumor 
cells to the entire complex of the cancer, inclusive of not only primary tumor cells but 
also of the microenvironment of said tumor.  Traditionally, cancer has been viewed as a 
disease characterized by mutating and transforming cells that acquire invasiveness and 
autonomous hyperproliferation, even in the presence of naturally occurring cell death 
signals.  In accordance with this model, therapy has historically centered on targeting the 
tumor cell itself [12].  As an alternative to traditional tumor cell directed therapy, 
targeting the tumor microenvironment offers a new area of focus with the possibility of 
developing many new, radical therapies to the treatment of cancer.  This new mode of 
thinking proposes to treat the tumor as an abnormal organ, inclusive of the molecules, 
signals and cell types that interact in an interdependent manner.   It has been proposed 
that this recognition of the tumor as a complex organ has potential to produce varying 
treatments to cancer that are not only more specific, but minimize toxicity and increase 
the patient’s chances of survival.  Furthermore, it is thought that targeting multiple 
components of the tumor microenvironment could in fact overcome escape mechanisms 
often implemented by the tumor [3, 13].   
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The Tumor Microenvironment 
 The aforementioned tumor microenvironment is a broad term inclusive of the 
supporting structures and cells in the immediate vicinity of the tumor.  These cells are 
normal, non malignant cells embedded within a conglomeration of protein rich 
extracellular matrix and interstitial fluid.  In addition to the stroma, and thus the blood 
vessels and supportive tissues, the various cell types accounted for in the tumor 
microenvironment are as follows: endothelial cells and their precursors, pericytes, smooth 
muscle cells, fibroblasts, carcinoma associated fibroblasts, myofibroblasts, neutrophils, 
eosinophils, basophils, mast cells, T and B lymphocytes, natural killer cells and antigen 
presenting cells such as macrophages and dendritic cells [12, 14].  It has been reported 
that these microenvironment cells exhibit an active role in cancer progression and tumor 
growth.  For example, the connection between inflammation and cancer has long been 
reported, with Rudolf Virchow reporting the infiltration of leukocytes in tumor tissue in 
1863 [15].  It was not deduced until later, however, that the recruitment of leukocytes 
actually promoted carcinogenesis under some circumstances.  Furthermore, inflammatory 
cells found in the tumor microenvironment, like monocytes and macrophages, contribute 
to the progression of the cancer by secreting different growth factors that influence tumor 
cell attributes like motility.  Monocytes and macrophages have been reported to secrete 
vascular endothelial growth factor (VEGF)- A and –C, basic fibroblast growth factor 
(bFGF), tumor necrosis factor (TNF), hepatocyte growth factor (HGF), epidermal growth 
factor (EGF) family members, platelet derived growth factor (PDGF), and chemokines 
like interleukin (IL)-8 [12].  The components of the microenvironment offer an outlet 
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through which tumors are able to progress through varying stages of angiogenesis and 
metastasis.   
 It is seen that tumor microenvironments have three very distinct and unique 
qualities: high interstitial pressure, hypoxia and low pH.  Hypoxia and acidosis result in 
an increasingly hostile metabolic microenvironment for the cells and tissues located 
within.  Under normal conditions, cells within the body require oxygen and other 
nutrients for growth and survival.  These parameters must be maintained in tissue 
homeostasis, as facilitated by an exchange of gas, nutrients and metabolites over capillary 
walls [14].  Tumor cells, however, present a unique case in terms of the previously 
mentioned homeostasis.  Due to the unique, uncontrolled proliferation of cells observed 
in tumors, the vasculature present in tumor cells is inadequate for maintaining 
homeostasis in regards to hydrogen ion flux, oxygen diffusion, and lymphatic pressure.  It 
is the interaction, or lack thereof, of tumor cells and tumor vasculature that results in 
regions of high interstitial fluid pressure (IFP), low oxygen tension, and low extracellular 
pH [16].  These three conditions are the current focus of much research as they facilitate 
the metastatic and angiogenic properties characteristic of the majority of invasive tumors.  
The processes resulting in hypoxia, low pH and high IFP will be discussed below in 
subsequent sections, as will the tumor cell adaptations that culminate in immunity to the 
conditionally evoked apoptosis observed in normal, non malignant cells [17].  
Furthermore, the increased metastatic and angiogenic potential resulting from said 
conditions will also be analyzed.   
Somatic Evolution of Tumor Cells 
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 As previously stated, cancer cells arise through mutations in the cell’s genome, 
mutations that result in cells with a phenotype characterized by uncontrolled proliferation 
due to the occurrence of oncogenes with dominant gain of function, along with a 
recessive loss of function in tumor suppressor genes.  These newly formed tumor cells 
exhibit, in addition to the aforementioned gain or loss of signals, an evasion of apoptosis, 
limitless replicative potential, sustained angiogenesis and the ability for metastasis [3].  
The transformation of these normal cells to benign, pre-malignant, tumor cells, and 
further to malignant, invasive tumor cells occurs through the process of somatic 
evolution.  This is said due to the analogy between carcinogenesis and Darwinian 
dynamics as new phenotypes are generated by heritable changes in gene expression and 
function [17].  These phenotypical changes actively selected for (immunity to hypoxia, 
low pH etc.) are directly dependent on the cell’s interactions with the 
microenvironmental selection forces.  The evolution of these cells coincides with an 
increase in communication between the microenvironment and tumor cells, as the tumor 
cells take advantage of the changes in the microenvironment [18].  Therefore, it can be 
assumed that the arising phenotypes being selected for offer a distinct advantage for the 
cell in terms of an increase in fitness and sustainability.   
Microenvironmental Hypoxia 
 Due to the large influence of hypoxia in the active selection of tumor cells, along 
with the subsequent increase in metastatic and angiogenic potential, a detailed description 
of the conditions that bring about this characteristic must be analyzed.  Under normal 
conditions, cells obtain the majority of their ATP from cellular respiration, inclusive of 
glycolysis, oxidative decarboxylation of pyruvate, the citric acid cycle and oxidative 
   8 
 
phosphorylation.  Under these conditions, the pyruvate created in glycolysis is oxidized 
to acetyl-CoA and CO2 by the pyruvate dehydrogenase complex.  Subsequently, in the 
presence of oxygen, this acetyl-CoA is transformed into oxaloacetate.  These steps, along 
with oxidative phosphorylation, result in the release of 36 ATP molecules (from one 
glucose molecule) [19].  
 Cellular respiration in the presence of oxygen (as previously described) is very 
efficient.  However, as stated, many metastatic tumor cells exist in a hypoxic 
environment.  This hypoxic environment arises due to limits in the oxygen diffusing 
capability found within tumors [18].  As a normal cell transforms into a pre-malignant 
cell it exhibits uncontrolled proliferation.  Thus, tumor cells are building upon tumor cells 
in the synthesis of the primary tumor.  Concurrent with cellular respiration, these cells are 
consuming large amounts of oxygen and glucose as they are rapidly dividing.  However, 
the tumor is highly heterogeneous in vascularity [19].  Normal, non-tumorogenic cells 
transform to tumorigenic cells characterized as hyperproliferative. As the 
hyperproliferative cells are building on top of each other, and the distance from the cells 
to the blood vessels is increasing, a diffusion limit is reached at which point the partial 
pressure of oxygen, pO2, is zero, and tumor cells must thus rely upon anaerobic 
glycolysis [18].   
The Warburg Effect 
As previously noted, tumor cells have evolved to exist in a hypoxic environment.   
The mechanism for this is described by the Warburg Effect which states that tumors 
develop a modified sugar metabolism in which a large portion of the blood glucose 
consumed by the tumor is converted one step beyond pyruvate into lactic acid, even 
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under normoxic conditions.  In other words, even when there is sufficient oxygen in the 
mitochondria to metabolize the pyruvate in glycolysis to carbon dioxide and oxygen, the 
glycolytic phenotype is still retained and responsible for the majority of the ATP formed 
by the cell.  The anaerobic glycolysis being carried out by these developing tumor cells is 
a highly inefficient process, releasing only 2 ATP molecules for every glucose molecule 
consumed [19-21].  It must also be noted that the glucose diffusion limit is further away 
from vessels than the oxygen diffusion limit, supporting further the beneficial effects for 
tumor cells to actively select for glycolysis.  Furthermore, this anaerobic glycolysis 
results in the release of lactic acid into the interstitial space, a process that brings about 
the low pH found in tumor microenvironments.  However, as the Warburg effect dictates, 
this phenotype is found even in the presence of oxygen, and must thus offer a distinct 
advantage for processes in the developing tumor cell like proliferation and biomolecule 
synthesis [18, 20, 22].   
 The work of Gatenby et al. presents a comparison of the rate of glucose 
consumption between a non invasive breast cancer line, MCF-7, and an invasive breast 
cancer line, MDA-MB-231, both in hypoxic and normoxic conditions.  The highly 
invasive line shows large amounts of glucose consumption both in normoxic and hypoxic 
conditions.  The non invasive line also exhibits glucose consumption in both conditions, 
however not nearly to the extent of the highly invasive line.  One can therefore observe 
the constant high rate of glycolysis of invasive cancer cells in aerobic and anaerobic 
conditions [19]. 
Microenvironmental Acidosis 
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 The upregulation of anaerobic glycolysis found in tumor cells results in the 
release of large amounts of lactic acid and carbonic acid into the microenvironment.  A 
trend is observed as the further the replicating cells are from the source of oxygen, the 
higher the dependency on anaerobic glycolysis, and thus the lower the pH is.   
Just as phenotypes that upregulate glycolysis are evolutionarily selected for, so 
must the phenotypes that are resistant to acid induced toxicity.  The exposure of 
peritumoral normal tissue to an acidic microenvironment brings about toxicity by two 
different mechanisms.  First, necrosis or apoptosis is invoked as the transmembrane 
hydrogen ion gradient collapses.  On top of this, the extracellular matrix also undergoes 
degradation through the release of proteolytic enzymes [23].  As the tumor cells have 
evolved to be immune to the acidosis mediated cell death, they are able to survive and 
proliferate in a low pH environment.  On the other hand, normal peritumoral cells are 
dying, permitting the acidosis resistant tumor cells to invade the available niche [23]. 
While the role of acidosis in promoting tumor cell invasion and metastasis has been 
proposed, little is known about whether there are any acidosis-responsive pathways that 
inhibit cancer metastasis.   
G-protein Coupled Receptors 
 G protein coupled receptors, GPCRs, are transmembrane cell surface receptors, 
composed of seven transmembrane alpha helices, responsible for transducing numerous 
extracellular signals into cells, along with playing important roles in the regulation of cell 
proliferation [24].  For example, GPCRs have a role in regulating neurotransmission, 
hormone and enzyme release from endocrine and exocrine glands, cardiac and smooth 
muscle contraction, immune responses and blood pressure regulation [25].  GPCRs are 
   11 
 
the largest family of receptors with over 800 members [26].  It has recently been 
discovered that GPCRs are deregulated in a large number of tumor cells, and it is thus 
thought that they may be involved in early tumor progression, tumor invasion and 
metastasis.  On the contrary, there have been reports that certain GPCRs, such as OGR1, 
inhibit tumor cell motility and metastasis by acting as metastasis suppressor genes, and 
the targeting of such genes offers high therapeutic potential [27].  GPCRs represent the 
target of 50-60% of all current therapeutic agents for various diseases, resulting in the 
most prominent family of pharmacological targets [25, 28]. 
Proton Sensing G-protein Coupled Receptors 
It has recently been discovered that the members of a GPCR subfamily, inclusive 
of GPR4, OGR1, TDAG8 and G2A, are proton sensors in cells through the activity of 
extracellular histidine residues.  OGR1, which shows the most homology to GPR4, has 
been seen to be inactive at a pH of 7.8, while fully active at a pH of 6.8, the pH observed 
in most tumor microenvironments [29, 30].  Experiments have confirmed the role of 
OGR1 in proton sensing, as a ligand independent activation of phosphinositide turnover 
is observed in cells (Inositol phosphate formation is stimulated by these proton sensing 
receptors).  At a pH of 7.6, IP formation was similar to that of the background, while a 
pH of 6.8 resulted in significant accumulation of IPs [29].  OGR1 has been seen to be a 
metastatic suppressor, as OGR1 expression is five times higher in primary tumor cells 
than metastatic tumor cells [30].  The work of Singh et al. illustrates the occurrence of 
OGR1 fluorescently tagged proteins as observed in tumors.  PC3 metastatic tumor cells 
were injected in the mouse prostate and allowed 45 days to adhere and metastasize. Their 
results indicated strong metastasis of the control primary prostate tumor cells to the 
   12 
 
stomach, diaphragm and spleen, while the OGR1 overexpressing tumor cells were 
contained to the prostate. Although ORG1 has been demonstrated to function as a proton 
sensor by several independent studies, Singh et al. showed that OGR1 inhibits cell 
migration in a pH independent manner in their experimental system. It remains to be 
determined whether their observation can be generalized in other cell systems.   Thus, 
OGR1 expression seems to play a vital role in inhibiting metastatic prostate cancer cell 
lines in a pH independent manner [30]. 
GPR4 
 As previously stated, GPR4 is a proton sensing GPCR sharing 40-50% homology 
to its family members OGR1, G2A and TDAG8.  GPR4 is widely expressed in a variety 
of tissues inclusive of the ovaries, liver, lung, kidney, lymph nodes, aorta, placenta, 
prostate, heart and many other tissues [29-31].   Research has implicated that activation 
of GPR4 leads to cyclic AMP production.  Furthermore, the extent of activation is 
directly correlated to decreases in pH [29].   The production of cAMP, and its 
downstream effecter protein kinase A, has been shown to inhibit angiogenesis.  It is 
therefore believed the GPR4 plays a role in the inhibition of angiogenesis at an acidic pH.  
Yang et al. have observed a fourfold decrease in microvessel outgrowth of GPR4 
expressing wild type aortic rings upon activation in an acidic environment when 
compared to GPR4 null aortic rings.  Furthermore, treatment of the GPR4 null mouse 
aortic rings with cAMP showed a significant inhibition of angiogenesis.  Therefore, it is 
currently believed that an acidic pH activates GPR4 to negatively regulated microvessel 
growth, consistent with cAMP production [24].  While this is a conclusive piece of data 
indicating not only the activation of GPR4 at an acidic pH, but also that this activation 
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causes a decrease in angiogenesis, more work needs to be carried out to analyze the role 
of GPR4 activation on tumor cell motility and metastasis.  Singh et al. reported that 
GPR4 overexpression has no effect on PC3 prostate cancer cell line migration, although 
they saw an inhibitory effect upon OGR1 overexpression.  Although they report no 
involvement of GPR4 in tumor cell migration inhibition, future studies need to be 
broadened so as to incorporate different tumor cell lines and varying pH treatments.  As 
acidosis activation of GPR4 has been reported to initiate different signaling pathways 
than OGR1, it is possible that the work of Singh et al. did not deduce all potential effects 
of GPR4 activation on tumor cell motility [30]. 
 Proton activation of GPR4, like its family members, regulates cell activity 
through coupling to Gs, G12/13 and Gq/11 proteins [32].  The Gs protein system leads to 
adenylate cyclase formation and accumulation of the downstream effecter cAMP.  The 
G12/13 signaling pathway leads to the activation of the small GTPase Rho and its 
downstream effectors ROCK1 and ROCK2.  Finally, the Gq/11 pathway is reported to 
result in the phospholipase C pathways along with NFAT-driven transcriptional 
activation [33]. 
 Various reports have indicated GPR4 activation by acidosis is associated with the 
upregulation of cAMP and Rho levels [29, 33, 34].  Liu et al. have suggested that GPR4 
does couple to multiple signaling pathways, inclusive of the G12/13 pathway, and that this 
coupling is proton induced.  Furthermore, Liu et al. highlighted the involvement of 
multiple histidine residues, specifically H79, H165 and H269, in the coupling of GPR4 to 
the Gs, G12/13 and Gq proteins [34].  
Tumor cell metastasis 
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 One of the most devastating aspects of cancer is the ability for cells to metastasize 
from the primary tumor to distant sites.  The incidence of metastasis is directly correlated 
with an increase in morbidity and mortality as lesions appear in distant organs, severely 
worsening the patient’s prognosis.  Surgery and specific types of radiation therapy are 
widely implemented to control sites of primary cancer formation, however they provide 
minimal help in controlling cancer cells once metastasis has been initiated. Often, 
chemotherapy, radiation and hormonal therapy are used in an attempt to retard metastasis, 
however results are commonly an extension of survival as opposed to complete 
eradication [21].  Therefore, it is of the utmost importance to develop novel strategies to 
inhibit the ability of tumor cells to metastasize, inclusive of preventing the acquisition of 
the invasive phenotype. 
 Although a complex process, the general steps involved in tumor cell metastasis 
require cancer cell motility, intravasation, transit in the blood or lymph, extravasation and 
finally arrest and growth at a new site [35].  Furthermore the final step, arrest and growth 
of tumor cells at a new site, is an impressively complex feat in itself.  Colonization is a 
term often used to describe the growth of a new tumor, as it requires the culminative 
organization of tumor cell proliferation, apoptosis and angiogenesis in the newly forming 
lesion [21].   
Tumor Cell Motility 
 The initial, propagating step of tumor cell metastasis is the ability of said cell to 
acquire an invasive phenotype through the acquisition of increased motility [36].  This 
motility arises through alterations in the tumor cell’s adherence to other cells and the 
extracellular matrix, along with the capability of said tumor cells to proteolytically 
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degrade the surrounding tissue and subsequently propel themselves through the newly 
created vacant space [21].  Often involved in the acquisition of the motile phenotype is an 
alteration of cell structure and characteristics in the form of an epithelial-to-mesenchymal 
transition (EMT).  Inclusive in the EMT is the loss of the epithelial cell-cell adhesion 
molecule E-cadherin in favor of the mesenchymal cell-cell adhesion molecule N-
cadherin, with this process being an indication of malignant progression [37].   Tumor 
cells also respond to secreted signals and proteases from many cells found in the tumor 
microenvironment, such as endothelial cells, fibroblasts, mesenchymal stem cells, 
endothelial cells and stromal cells, with the signals from these cells acting as modulators 
of invasion and migration [38].   
 The ability for propulsion and movement through open space is mediated through 
cytoskeleton rearrangement interactions with the cells in the tumor microenvironment.  
The exact mechanism for this motility, however, is incredibly diverse among different 
cell types.  There are many different types of motility styles, and they are defined by their 
differences in integrin-mediated cell matrix adhesion, cadherin mediated cell-cell 
adhesion, cell polarity, extracellular protease activities, and the cytoskeletal arrangement 
[39].   
 In general, cell migration in the extra cellular matrix has five hallmark steps.  The 
first of these steps is lamellipodium extension at the leading edge, often requiring leading 
edge actin polymerization.  The second step is the formation of new focal adhesion 
complexes at the extending edge of the cell via the interaction of integrins with extra 
cellular matrix ligands.  Next comes proteolysis of the extra cellular matrix due to the 
activity of proteases.  The fourth step is the actomyosin contractions due to myosin II 
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binding to actin filaments.  Finally comes tail detachment at the trailing edge, generating 
a contractile force that coordinates with that of the actomyosin contractions [39, 40]. 
 The aforementioned steps are general characteristics of tumor cell motility.  
Within differing types of cells, however, exist three primary modes of motility.  These 
three primary modes of motility are single-cell amoeboid, single cell mesenchymal 
migration, or collective cell migration [41]. Cells undertaking amoeboidal migration have 
a rounded phenotype void of mature focal adhesions [42].  This form of motility utilizes a 
propulsive and pushing mechanism as opposed to relying on adherence to the substrate 
and subsequent pulling [41].  Amoeboidal motility does not require the activity of 
proteases, as cells are able to squeeze through gaps in the extracellular matrix as opposed 
to degrading it [43].  In opposition to amoeboidal motility is mesenchymal motility, 
which requires high levels of attachment via focal adhesion complexes and cytoskeletal 
contractility [41].  Cells undergoing mesenchymal motility are characterized by fibroblast 
like, elongated cell morphology.  Furthermore, these cells have established polarity and 
their invasion is dependent upon proteolysis degradation of the ECM [39].  Finally, 
collective cell motility involves the migration of sheets, strands and clusters of cells that 
maintain cell-cell junctions.  Parts of the pathway resulting in collective cell motility are 
similar to that resulting in mesenchymal motility, however the exact mechanisms of this 
form of motility have much to be deduced [39, 41]. 
Role of the G12/13-protein/Rho Signaling Pathway in Tumor Cell Motility 
 There is no doubt as to the necessity of cytoskeletal rearrangement in cell motility 
and metastasis.  It is thought that the activation of Rho and the subsequent activation of 
Rho kinases (ROCK1 and ROCK2) is specifically involved in cell contractility and 
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cytoskeletal rearrangement.  This suggests a possible involvement of the Rho/Rho kinase 
pathway in different aspects of metastasis, specifically cell migration, invasion, cell-cell 
adhesion and actomyosin contraction [34].  While many reports have indicated the 
involvement of Rho in cell motility [44], cell movement is a very complex procedure 
with many factors contributing towards its progression or inhibition.  The process of 
cancer cell migration is a culmination of the coordination between cytoplasmic 
membrane protrusions in leading lamellipodia, new adhesions at the leading edge, new 
organization and construction of filaments throughout the cell body, and finally 
detachment at the tailing edge.  The Rho family of GTPases (Rho, Rac and Cdc42) plays 
a role in cell motility with Rac and Cdc42 regulating lamellipodia and filopodia 
formation and direction of motility, Rho assisting in the formation and maintenance of 
focal adhesions and the formation of actin stress fibers, and ROCK contributing towards 
myosin light chain phosphorylation and subsequent actomyosin based contractility [36, 
39, 44]. 
 While it is clear that the Rho family of GTPases contributes, in many areas, to cell 
motility, a fine equilibrium must be obtained to ensure this movement.  The motility of 
mesenchymal like cells that have an elongated, fibroblast like phenotype proves to be a 
balancing act of sorts.  It is reported that the activity of RhoA and its effector ROCK 
needs to be reduced to extend protrusions at the leading edge of the cell, a crucial aspect 
for cell motility [45, 46].  It is therefore thought that inhibiting these proteins in 
mesenchymal like cells will return minimal effects [39].  The work of Vial et al. found 
that elevated levels of activated Rho inhibited colon carcinoma cell motility, with this 
phenotype being attributed to an increase in stress fiber formation and focal adhesions, 
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which subsequently inhibits protrusions and cell motility [36].  Therefore it is evident that 
a tight control of Rho activity is crucial to balance cell contraction and adhesion. 
 As previously mentioned, one of the prominent pathways activated by proton 
induced activation of GPR4 is the G12/13
 
signaling pathway, as indicated by an 
upregulation in activities of a Rho pathway reporter construct [33, 34].  This pathway has 
been reported to be activated by other G-protein coupled receptors, inclusive of OGR1 
and S1P2 [33, 47].  Furthermore, Takashima et al. reported that S1P2 induced activation 
of Rho inhibited migration in vascular smooth muscle cells [47, 48].  These reports 
coincide with other findings that Rho is upregulated in tumor cell motility inhibition as 
Vial et al. demonstrated a necessary downregulation of Rho-GTP levels in the promotion 
of colon carcinoma cell migration [36].  There is clearly a direct link between an 
upregulation of the G12/13/Rho pathway and acidosis activation of GPR4, however the 
effects of this activation on tumor cell migration and motility have yet to be deduced. 
 
 
Chapter 2:  Materials and Methods 
 
 The B16F10 mouse melanoma, TRAMP-C1 mouse prostate cancer, NIH3T3 
mouse embryonic fibroblast cell lines, and primary HUVEC human umbilical vein 
endothelial cells were used for these experiments.  All mouse cell lines express residual 
levels of endogenous GPR4 (mGPR4).  B16F10, TRAMP-C1, and NIH3T3 cells were 
originally from American Type Culture Collection (ATCC), and HUVEC cells were 
obtained from Cambrex (now a part of Lonza). Dr. Li Yang from the Department of 
Internal Medicine/Division of Hematology/Oncology at the East Carolina University 
Brody School of Medicine provided the cancer cell lines along with all the materials and 
funding for these experiments. 
 Dr. Yang was also responsible for the design and development of the cell lines 
used. The open reading frame of human GPR4 (GenBank accession number NM 005282) 
was amplified from human cDNA samples by polymerase chain reaction (PCR) with the 
high-fidelity pfu-turbo DNA polymerase (Stratagene, La Jolla, CA). The PCR primer pair 
was: sense strand 5’- ATAAGAATGCGGCCGCACCATGGGCAACCACACGTG -3’ 
and antisense strand 5’- ATAAGAATGCGGCCGCTCATTGTGCTGGCGGCAGCAT -
3’. A NotI restriction enzyme cut site was engineered at each end of the PCR fragment 
and the Kozak consensus sequence was added before the translation start codon ATG to 
achieve efficient translation. The amplified PCR fragment was digested with the NotI 
restriction enzyme and cloned into the retroviral expression vector MSCV-IRES-GFP as 
previously described [49]. The resulted construct, named MSCV-huGPR4-IRES-GFP, 
was sequenced from both strands to verify no mutations existing in the coding region. To 
make stable cell lines, retroviral transduction was performed as previously described 
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[49].  Briefly, the MSCV-huGPR4-IRES-GFP or MSCV-IRES-GFP retroviral vector was 
co-transfected with the pCL10A-1 packaging vector into HEK 293T cells to produce 
retroviral particles, which were used to transduce B16F10 and TRAMP-C1 cells to make 
stable cell lines. As the retroviral vector expresses the GFP marker, cells with stable 
exogenous gene expression were selected by the GFP signal using a fluorescence 
activated cell sorter (FACS). 
Cell Culture 
B16F10 and NIH3T3 cells were both maintained in Dulbecco’s Modified Eagle’s  
Medium (DMEM) (Gibco) supplemented with 10% Fetal Bovine Serum (FBS) 
(Invitrogen). TRAMP-C1 cells were maintained in DMEM with 5% FBS, 5% Nu-Serum 
IV (Invitrogen), 5ug/mL Insulin-Transferrin-Selenium-X (Gibco), and 0.01nmol/L 
dihydrotestosterone (Gibco).  HUVEC cells were grown in Endothelial Cell Growth 
Medium-2 (EGM-2) (Lonza).  All cells were cultured in a tissue culture incubator at 37
o
C 
with 5% CO2.  0.25% Trypsin-EDTA (Gibco) was used for cell detachment.  Dulbecco’s 
Phosphate Buffered Solution 1x (dPBS) (Gibco) was used for cell washing.  For 
experiments involving pH, 7.5mM HEPES, 7.5mM EPPS [N-(2-hydroxyethyl)-
piperazine-N’-3-propanesulfonic acid], and 7.5mM MES [2-(4-morpholino) 
ethanesulfonic acid] (HEM) was used in conjunction with 5N NaOH and 5N HCl to 
buffer the appropriate media to the desired pH.  All cells were grown on 60mm or 
100mm culture plates (Corning).  All cells used in the following experiments were passed 
for 2-10 generations and care was taken to prevent growth greater than 90% confluency.  
RT-PCR 
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RNA extraction was performed as recommended by the RNeasy Plus Mini Kit 
(Qiagen).  All solutions and reagents were obtained from the kit.  Cells were grown to 
less than 90% confluency on a 10cm plate and lysed with 600µL of Buffer Rlt Plus.  
Lysate was collected and passed 5 times through a 20 gauge needle fitted to an RNAse 
free syringe.  Lysate was then transferred through a gDNA eliminator spin column placed 
in a 2mL collection tube.  The column was then spun for 30 seconds at greater than 
10,000 rpm, at which point the column discarded and the flow through saved.  600µL of 
70% ethanol was then added to the flow through and mixed well.  The sample was then 
transferred to an RNeasy spin column placed within a 2mL collection tube.  The tube was 
then spun for 15 seconds at 10,000 rpm.  The flow through was then discarded and 700µL 
of Buffer RPE was added to the RNeasy spin column and centrifuged for 15 seconds at 
10,000 rpm.  The flow through was once again discarded and 500µL of Buffer RPE 
added to the RNeasy spin column.  The column was centrifuged for 2 minutes at 10,000 
rpm.  The column was removed from the collection tube, placed in a new 2mL collection 
tube, and centrifuged for 1 minute at 10,000 rpm.  After placing the column in a new 
1.5mL collection tube, 50µL of RNase-free water was added to the spin column 
membrane and centrifuged for 1 minutes at 10,000 rpm to elute the RNA. 
To convert the RNA to cDNA, 1µL of Random Primer was added to 5µg RNA 
and the volume was adjusted to 12µL with sterile, Rnase free distilled water.  Next, the 
mixture was heated to 70°C for 10 minutes and chilled on ice.  The contents of the tube 
were collected by brief centrifugation, and 4µL of 5X First Strand Buffer (250mM Tris-
Cl, pH 8.3, 375mM KCl, 15mM MgCl2), 2µL of 0.1M DTT, and 1µL 10mM dNTP mix 
(10mM each dATP, dGTP, dCTP, and dTTP at neutral pH).  The contents were mixed 
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and incubated at room temperature for 12 minutes.  1µL of SUPERSCRIPT II was then 
added and gently pipette up and down.  The mixture was then incubated for 50 minutes at 
42°C.  The reaction was inactivated by heating at 70°C for 15 minutes, leaving the cDNA 
product. 
The following reagents (Invitrogen) and volumes were used per cDNA sample for 
the PCR reaction: 
 2µL cDNA 
 1µL primers (10µM each) 
 2.5µL 10x Buffer 
 0.75µL 50mM MgCl2 
 0.5µL 10mM dNTPs 
 18µL H2O 
 0.25µL Taq (5 U/ µL) 
The PCR primer pair used for huGPR4 amplification was: sense strand 5’- 
ACCTCTATCGGGTGTTCGTG -3’ and antisense strand 5’- 
TGCCTGCAAAGGGTCGCTAC -3’.  For mGPR4 activation, the primer pair used was 
sense strand 5’- CAAGACCCACTTGGACCACA -3’ and antisense strand 5’- 
TGTCCTGGGCCTCCTTTCTA -3’.  35 Cycles were performed at an annealing 
temperature of 58°C. 
For quantification, Gel Pro Analyzer software (Media Cybernetics) was used.  
The optical density was determined for each sample and normalized to the β-Actin 
internal control.  The fold ratio of amplification was then determined in comparison to 
the least amplified signal (mGPR4 of TRAMP-C1/GPR4 cells). 
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Transwell Migration and Invasion Assays 
B16F10 and TRAMP-C1 cells were grown to 50-75% confluency on 10cm cell 
culture plates.  The cells were then washed in dPBS, trypsinized, stained with Trypan 
blue to ensure viability, and counted using a hemacytometer.  1x10
5
 tumor cells were 
resuspended in 100 L of pH buffered DMEM with 0.1% BSA (Sigma) (migration 
media), and applied to the top of a transwell membrane with 8µm pores. For a 
chemoattractant, NIH3T3 cells were grown for three days, the growth media collected, 
pH buffered, and 600 L applied to the bottom of each transwell.    Following migration, 
cells were fixed for 10 minutes with 70% ethanol and allowed to dry, then stained for 10 
minutes with 0.2% Crystal Violet (Sigma) and three different fields counted using a 10x 
objective under an inverted microscope.    
 To resemble invasion through the extra cellular matrix (ECM), 50 L of an ice 
cold 1:2 dilution of matrigel:ice-cold water, thawed on ice, was applied evenly and void 
of bubbles to the top of each transwell and allowed to incubate for 1 hour prior to 
introducing 1x10
5
 B16F10 or TRAMP-C1 cells resuspended in 100 L of pH buffered 
migration media.  NIH3T3 3-day pH buffered conditioned media was then applied to the 
bottom of the transwell and cells allowed to invade.  Following invasion, the matrigel and 
migration media was removed, and the cells fixed, stained, and counted as previously 
described. 
 To resemble invasion through an endothelial cell monolayer, 1x10
5
 HUVEC cells 
were added to the top of each transwell, with EGM-2 added to the lower well, and 
allowed to grow to confluency for 24 hours, at which point B16F10 or TRAMP-C1 cells 
were introduced and allowed to invade as previously described.  Prior to their detachment 
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and introduction to the transwell, the tumor cells were stained for 30 minutes using 2mM 
cell tracker orange (Invitrogen) so as to distinguish invading tumor cells from endothelial 
cells.  Invaded tumor cells were counted using a fluorescent microscope. 
Wound Closure Assay 
 2.5x10
5 
B16F10 or TRAMP-C1 tumor cells were plated in individual wells of a 
24 well plate and allowed 24 hours to attach and grow to confluency.  A 10 L pipette tip 
was then used to create a wound through the center of the confluent cell layer.  Cells were 
then treated with 1mL of the appropriate pH buffered growth media, either DMEM + 
10% FBS for B16F10 cells or TRAMP media for TRAMP-C1 cells.  Photos were taken 
of the wound periodically throughout the assay.  To quantify the data, the size of the 
wound was determined at the beginning of the assay and compared to the size of the 
wound upon assay commencement.  This analysis gave the distance ( m) that the tumor 
cells were able to close the wound. 
 For wound closure assays involving the treatment with the known cell permeable 
Rho activator CN01 (Cytoskeleton, Inc.), 0.5unit/mL CN01 or 2.5 L/mL DMSO (CN01 
solvent) was added to the appropriate pH buffered growth media. 
Rhodamine Phalloidin Staining of Actin Stress Fibers 
 B16F10 cells were grown to less than 50% confluency on an 8-chambered slide 
(Lab-Tek), at which point they were serum starved by treating with DMEM + 1% FBS 
for one day and DMEM + 0% FBS for two days.  Tumor cells were then treated with pH 
buffered DMEM or DMEM + 0.5unit/mL CN01.  After treatment, the cells were washed 
with 37ºC dPBS and fixed with a fixative solution consisting of 10% Formaldehyde 
(Fischer) and 90% dPBS.  Next, dPBS was used to wash the cells and they were 
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permealized with a permealization buffer consisting of 5% Triton X-100 (Bio Rad) and 
95% dPBS.  Cells were then stained with 100nM Rhodamine Phalloidin (Cytoskeleton) 
and incubated in the dark for 30 minutes.  Mounting media with DAPI (Vector) was then 
applied and the actin fibers observed using a fluorescent microscope. 
Extra Cellular Matrix Degradation Assay 
 To analyze degradation of the extra cellular matrix, 0.2% gelatin (Sigma) was 
conjugated with Alexa Fluor 555 (Molecular Probes).  Alexa Fluor 555 is known to have 
a succinimidyl ester moiety that reacts with primary amines to form protein-dye 
conjugates.  Protein-dye conjugation was performed as dictated in the Alexa Fluor 555 
Protein Labeling Kit and is summarized below.  50 L of a 1 M solution of the provided 
sodium bicarbonate was added to 0.5mL of 2mg/mL gelatin.  This protein solution was 
then added to the provided vial of Alexa Fluor 555 dye and the dye dissolved completely 
for 1 hour at room temperature.  Next, the provided purification resin was packed into the 
provided column and the gelatin-dye solution added to the top.  The provided elution 
buffer was used to elute the labeled protein through the column.  A UV lamp was used to 
observe the elution of the labeled protein and the first fluorescent band collected.  The 
sample collected was the protein-dye conjugate. 
 To confirm conjugate of the gelatin with the Alexa Fluor 555 dye, gel 
electrophoresis was run on the gelatin protein and gelatin-Alexa Fluor 555 conjugate.  
The gel was washed three times for 15 minutes with 15mL of deionized water.  20mL of 
GelCode Blue Stain Reagent (Thermo Scientific) was used to stain the gel for 1 hour.  
The stained gel was then washed for 1 hour with ultrapure water, with the water being 
changed periodically.  Samples were observed under white light and UV light. 
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 The confirmed gelatin-Alexa Fluor 555 conjugate was then applied to the top of 
18mm cell culture coverslips in the following manner.  Coverslips were autoclaved and 
placed in individual wells of a 12 well cell culture plate, at which point each coverslip 
was treated with 1mL of a 0.5 g/mL solution of Poly-L-Lysine (Sigma) for 20 minutes.  
Slips were then washed three times with 1mL of dPBS containing calcium chloride and 
magnesium chloride (Sigma).  After the third wash, coverslips were coated with 1mL of 
0.5% glutaraldehyde (Electron Microscopy Sciences) and incubated for 15 minutes at 
room temperature.  Coverslips were again washed three times with the aforementioned 
dPBS, however it was not aspirated after the third wash.  The Alexa Fluor 555-gelatin 
conjugate was mixed at an 1:8 ratio with 0.2% gelatin and placed in a 37 C water bath.  
Parafilm was pressed to the workbench to prevent sliding and 80uL of the 1:8 Alexa 
Fluor 555-gelatin:0.2% gelatin mixture deposited on the parafilm.  Coverslips were lifted 
with forceps and a needle and inverted on the drops of gelatin matrix.  Coverslips were 
allowed 10 minutes to incubate at room temperature at which point they were stored at 
4 C. 
 2x10
4
 B16F10 cells, resuspended at 2x10
4
 cells/mL, were introduced to the top of 
each coverslip.  Cells were allowed 8 hours to attach at which point they were treated 
with pH buffered growth media.  After 28 hours degradation was observed via 
fluorescent microscopy.  Analysis was performed by counting the cells per area under the 
bright field and comparing this to the number of degraded regions corresponding to cells.  
Furthermore, the area of degradation was analyzed using ImageJ (NIH) software.  Photos 
were also taken at the 28 hour mark. 
Claudin-1 Western Blot Analysis 
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HUVEC cells transduced with the MSCV-IRES-GFP vector were grown in EGM-
2/HEM medium at pH 8.4 until 90% confluent. Cells were then treated with EGM-
2/HEM media at pH 8.4, 7.4, or 6.4 for 15 hours, and lysed in ice-cold RIPA lysis buffer 
(50mM Tris-HCl, pH 7.4, 150mM NaCl, 1% Triton X-100, 0.25% Na-deoxycholate, 
1mM EDTA, 1mM phenylmethylsulfonyl fluoride, 1mM Na3VO4, 1mM NaF, 5% 
protease cocktail inhibitor) (Sigma) for 15 minutes at 4
o
C. The cell lysates were clarified 
by centrifugation at 14,000 × g for 15 minutes at 4
o
C. Protein concentration of the 
supernatant was determined by the Bradford protein assay (Bio-Rad, Hercules, CA). 15-
20µg cell lysates were separated on a 4-12% Bis-Tris gel (Invitrogen). The expression of 
Claudin-1 was analyzed by Western blotting with the rabbit polyclonal anti- Claudin-1 
antibody (Invitrogen), followed by the incubation with the horseradish peroxidase (HRP)-
conjugated goat anti-rabbit IgG secondary antibody (Santa Cruz Biotechnology). 
Chemiluminescence signals were detected using the Amersham ECL Advance Western 
blotting detection kit (GE Healthcare). 
Care of Laboratory Animals 
Male and female C57BL/6 mice, 6-8 weeks old, were purchased from The 
Jackson Laboratory (Bar Harbor, Maine) and bred at the ECU animal facility.  All mice 
were cared for and housed according to current IACUC regulations.  Mice were kept on a 
12 hour light/dark cycle in a climate controlled room at the ECU Brody School of 
Medicine Department of Comparative Medicine.  All female mice used in the current 
studies were C57BL/6 wildtype. 
Pulmonary Melanoma Metastasis 
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 To observe the in vivo metastatic ability of B16F10 melanoma cells, a tail vein 
assay was performed to observe pulmonary metastasis.  B16F10 cells were grown to 50-
75% confluency on 10cm cell culture plates, trypsinized, and washed twice with ice cold 
dPBS, at which point the cells were counted using a hemacytometer.  Tumor cells were 
then resuspended at a concentration of 4x10
5
 cells/mL in ice cold dPBS.  8-14 week old 
C57BL/6 female mice were place in a mouse holder and their tails submerged in warm 
distilled water to dilate the blood vessels. 2x10
5
 cells, resuspended in 0.5mL ice cold 
dPBS, were injected into the lateral tail vein. Intravenous tumor injections allow for the 
transport of cells throughout the vasculature and offer a model for the eventual arrest, 
extravasation and subsequent colonization of tumor cells in the lung complexes.  This 
procedure is commonly used for the evaluation of metastasis in a murine model [50].  
Mice were observed daily for morbidity and general health until being euthanized by CO2 
asphyxiation 16 days post injection.  The lungs were then dissected and fixed in Fekete’s 
Solution (100mL 70% ethanol, 10mL formalin, and 5mL acetic acid) and the tumor 
nodes counted using a dissecting microscope. 
 For tail vein injections involving treatment with the known Rho activator CN01, 
tumor cells were pretreated for two hours with 0.5unit/mL CN01 or 2.5 L/mL DMSO in 
serum free DMEM.  The remaining steps are identical as above. 
Subcutaneous Melanoma Injection 
This assay allows for the visualization of a subcutaneous primary tumor in a 
precise, predetermined area, and is widely used as an accepted model for the evaluation 
of primary tumor growth [50].  B16F10 cells were grown to 50-75% confluence on 10cm 
cell culture plates.  Cells were then washed with ice-cold dPBS, trypsinized, resuspended 
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twice in ice-cold dPBS, counted, and resuspended at 1x10
6
 cells/mL in ice-cold dPBS.  
Mice were then anesthetized with 0.05mL/10g body weight of a 9:1 mixture of Ketamine 
to Xylazine (provided by the ECU Department of Comparative Medicine) and shaved 
using an electric razor. 2x10
5 
cells were then injected subcutaneously into the right hip 
flank of the mouse and a primary tumor allowed to form.  Primary tumor measurements 
were taken every three days and mice examined for morbidity and general health.  Mice 
were euthanized by CO2 asphyxiation after 14 days, at which point the tumors were 
dissected, fixed, and weighed.  For subcutaneous melanoma injections involving the 
known Rho activator CN01, tumor cells were pretreated for two hours with 0.5unit/mL 
CN01 or 2.5 L/mL DMSO in serum free DMEM.  The remaining steps are identical as 
above. 
MTT Assay 
B16F10/Vector and B16F10/GPR4 cells were plated at 5x10
3
 cells/well in a 96 
well plate and allowed 2 hours to attach, at which point cells were treated with pH 
buffered growth media.  15 L of MTT Dye (Promega) was then added to each wells and 
allowed 2 hours to incubate.  After incubation, 100 L of stop solution (Promega) was 
then administered to each well and the precipitate thoroughly resuspended.  The plate was 
then read at 570nm and 650nm using a spectrophotometer to determine the MTT ratio.  
Plates were read at the same time for three consecutive days, with care being taken to 
refresh the pH buffered growth media.  
Statistical Analysis 
 Statistical analysis was carried out using Prism software.  Non-paired t-tests were 
performed with *P<0.05, **P<0.01, and ***P<0.001. 
Chapter 3: Results 
Confirmation of huGPR4 Overexpression in B16F10 and TRAMP-C1 Cells 
 B16F10 mouse melanoma and TRAMP-C1 mouse prostate cancer cell lines were 
stably transduced with human GPR4 (huGPR4) to investigate its function in the 
mentioned cancer cell lines.  As illustrated in Figure 1, RT-PCR confirmed that the 
huGPR4 transcript is only expressed in the B16F10/MSCV-huGPR4-IRES-GFP 
(B16F10/GPR4) and TRAMP-C1/MSCV-huGPR4-IRES-GFP (TRAMP-C1/GPR4) cell 
lines, and that the B16F10/MSCV-IRES-GFP (B16F10/Vector) and TRAMP-C1/MSCV-
IRES-GFP (TRAMP-C1/Vector) cell lines contain only the empty vector.  Furthermore, 
as expected, there were equal, low levels of endogenous mouse GPR4 (mGPR4) 
amplification in all four cell types. 
GPR4 Activation in an Acidic Environment Inhibits Tumor Cell Motility 
 A wound closure assay was performed to analyze the effect of GPR4 
overexpression and subsequent activation on tumor cell migration. After creating a 
wound in a confluent monolayer of tumor cells, the cells were then treated with pH 
buffered growth media and their ability to close the wound observed.  This data 
established that GPR4 is activated at an acidic pH, and that activation of GPR4 results in 
an alteration of the motility phenotype in B16F10 and TRAMP-C1 tumor cells.  Tumor 
cells that overexpressed the vector showed only a slight inhibition of motility at an acidic 
pH, which could be attributed to the expression of residual levels of mGPR4 or other 
currently unknown reasons.  However, upon full activation of overexpressed GPR4 at a 
pH of 6.4, there was a significant (p<0.05) inhibition of the ability for wound closure 
when compared to vector cells at pH 6.4 and GPR4 overexpressing cells at pH 7.9 
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Figure 1.  RT-PCR Amplification of huGPR4 and mGPR4 in B16F10 and TRAMP-
C1 Cells.  (A)  Images of RT-PCR amplification of huGPR4, mGPR4 and β-Actin.  RT-
PCR was performed on RNAs isolated from B16F10/Vector, B16F10/GPR4, TRAMP-
C1/Vector and TRAMP-C1/GPR4 cells.  Primers were designed to amplify either the 
huGPR4-IRES sequence or mGPR4.   Actin was used as an internal control and the 
water used during the assay as a negative control.  (B)  Quantification of RT-PCR 
amplification of huGPR4, mGPR4 and β-Actin.  The optical density was measured for 
each sample and normalized to the β-Actin internal control.  A fold ratio was then 
determined for quantification of the amplification. 
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 (Figure 2).  This phenotype was observed for both B16F10/GPR4 and TRAMP-
C1/GPR4 cells and implies an inhibition of cell motility upon complete activation of 
GPR4.  Figure 2 offers both a qualitative (2A) and quantitative (2B, 2C) representation of 
this data. 
GPR4 Activation in an Acidic Environment Inhibits Tumor Cell Directional Migration  
 After determining that GPR4 was activated at an acidic pH, and that this 
activation brings about an inhibition of motility in B16F10 and TRAMP-C1 tumor cells, 
it was next important to analyze the effects of this activation on directional migration 
(chemotaxis) as revealed by transwell assays.  Transwell migration assays were used as a 
model to observe the ability for chemotaxis of the different tumor cell lines at varying 
pH.  Cells were allowed to migrate from pH treated serum free migration media, through 
an 8 m-pored transwell filter, towards pH treated NIH3T3-conditioned growth media.  
As fibroblast cells secrete a variety of growth factors, chemokines and cytokines, and are 
an integral part of the extra cellular matrix, their growth media was used as a 
chemoattractant in the migration assay to mimic the fibroblastic tumor 
microenvironment.   This assay allowed for the visualization and quantification of the 
effect of GPR4 activation on directional migration, and a significant inhibition of the 
ability for migration was observed upon full activation of GPR4 in different cell lines.  
As can be observed in Figure 3, upon overexpression and activation of GPR4 there was a 
significant (p<0.05) inhibition in the ability for directional chemotaxis in both B16F10 
and TRAMP-C1 tumor cells as indicated by the number of cells that migrated through the 
transwell filter (3A, 3C).  Images were taken of the transwell filters, with migrated cells 
stained purple (3B, 3C).  There is a noticeable
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Figure 2.  B16F10 and TRAMP-C1 Cell Wound Closure Assays.  (A)  Images of 
B16F10 and TRAMP-C1 wound closure.   Images were taken of B16F10/Vector and 
B16F10/GPR4 cells at the 0 and 11 hour marks.  Cells were treated with growth media 
pH buffered to 7.9, 7.4, 6.9 or 6.4. (B)  Quantification of B16F10 wound closure.  The 
extent of wound closure was quantified by measuring the distance cells traveled ( m) 
after 11 hours.  These results are the average of three independent experiments.  (C)  
Quantification of TRAMP-C1 wound closure.  The extent of wound closure was 
quantified by measuring the distance cells traveled ( m) after 6 hours.  These results are 
the average of three independent experiments. *P<0.05, **P<0.01, and ***P<0.001, 
compared to Vector cells at each pH. 
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inhibition of migration upon the overexpression and subsequent activation of GPR4 in the 
tumor cells. 
 GPR4 Activation Inhibits the Ability for Invasion Through the Extra Cellular Matrix  
 
 As it was deduced that GPR4 activation by acidosis inhibits both the spontaneous 
motility and directional migration of B16F10 and TRAMP-C1 tumor cells, it was next 
necessary to analyze the effect of GPR4 activation on tumor cell invasion through the 
extra cellular matrix (ECM).  With the ability for degradation and subsequent invasion 
through the ECM being an integral part of tumor cell metastasis, transwell invasion 
assays through a layer of matrigel were performed in an attempt to mimic this process.  
Matrigel is designed to resemble the dense stroma and connective tissue that is 
characteristic of the ECM.  Ice cold matrigel was applied to the top of 8 m transwell 
filters, and cells were allowed to migrate from pH buffered migration media, through the 
matrigel and transwell filter, towards pH buffered NIH3T3-conditioned media.  
Overexpression and activation of GPR4 by acidosis, especially at a pH of 6.4, 
significantly inhibited the ability for B16F10/GPR4 and TRAMP-C1/GPR4 cells to 
invade through the matrigel layer (Figures 4A and 4B).  Figure 4 illustrates a pH 
dependent decrease in the invasive capability of B16F10/GPR4 and TRAMP-C1/GPR4 
cells in comparison to B16F10/Vector and TRAMP-C1/Vector cells. 
GPR4 Activation Decreases the Ability for Tumor Cells to Degrade Gelatin 
 To further elucidate the mechanism by which GPR4 activation inhibits the 
invasion of tumor cells through the extra cellular matrix, a gelatin degradation assay was 
performed with the intent to analyze how GPR4 activation affects the ability for tumor  
cell degradation.  Degradation of the ECM is an important step in tumor cell invasion and 
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Figure 3.  B16F10 and TRAMP-C1 Transwell Migration Assays.  (A)  B16F10 
transwell migration assay at varying pH. 1x10
5 
B16F10/Vector or B16F10/GPR4 cells 
were allowed 6 hours to migrate from pH buffered serum free migration media, through a 
transwell filter with 8 m pores, to pH buffered NIH3T3 conditioned media.  Migrated 
cells were stained with 0.2% crystal violet and counted using a 10x objective.  Three 
fields were counted for each filter.  These results are the average of three independent 
experiments.  (B)  Photos of B16F10 chemotaxis migration assay.  Photos were taken of 
the transwell filters after the fixing and staining of migrated cells.  (C)  TRAMP-C1 
transwell migration assay at varying pH. 1x10
5 
TRAMP-C1/Vector or TRAMP-C1/GPR4 
cells were allowed 3 hours to migrate from pH buffered serum free migration media, 
through a transwell filter with 8 m pores, to pH buffered NIH3T3 conditioned media.  
Migrated cells were stained with 0.2% Crystal Violet and counted using a 10x objective.  
Three fields were counted for each filter.  These results are the average of three 
independent experiments.  (D)  Photos of TRAMP-C1 chemotaxis migration assay.  
Photos were taken of the transwells after the fixing and staining of migrated cells. 
**P<0.01 and ***P<0.001, compared to Vector cells at each pH. 
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Figure 4.  B16F10 and TRAMP-C1 ECM Invasion Assays.  (A)  B16F10 transwell 
ECM invasion assay at varying pH.  1x10
5
 B16F10/Vector or B16F10/GPR4 cells were 
resuspended in pH buffered migration media, applied to the top of a 50 L layer of a 2:1 
mixture of water:matrigel, and allowed 20 hours to invade towards pH buffered NIH3T3 
conditioned media.  Migrated cells were stained with 0.2% crystal violet and counted 
using a 10x objective.  Three fields were counted for each transwell filter.  These results 
are the average of two independent experiments.  (B)  TRAMP-C1 transwell ECM 
invasion assay at varying pH.  1x10
5
 TRAMP-C1/Vector or TRAMP-C1/GPR4 cells 
were resuspended in pH buffered migration media, applied to the top of a 50 L layer of a 
2:1 mixture of water:matrigel, and allowed 16 hours to invade towards pH buffered 
NIH3T3 conditioned media.  Migrated cells were stained with 0.2% crystal violet and 
counted using a 10x objective.  Three fields were counted for each transwell filter.  These 
results are the average of two independent experiments.  *P<0.05, **P<0.01 and 
***P<0.001, compared to Vector cells at each pH. 
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metastasis as cells must first degrade their immediate environment so as to expose a niche 
for their invasion.  Therefore, plating cells on top of fluorescently labeled gelatin and 
allowing them to attach and enter the cell cycle offered a means to observe degradation of 
the gelatin by the tumor cells, indicative of degradation of the ECM.  A 0.2% gelatin and 
Alexa Fluor 555 conjugate was purified and confirmed via coomassie blue staining and 
gel electrophoresis.  Analysis under white light revealed identical patterns of bands 
between 0.2% gelatin and the 0.2% Gelatin/Alexa Fluor 555 conjugate. The sizes of the 
bands of the Gelatin/Alexa Fluor 555 conjugate were slightly larger than those of gelatin 
only, likely due to the conjugation of the Alexa Fluor 555.   As expected, under UV light, 
only the 0.2% Gelatin/Alexua Fluor 555 conjugate offered bands, confirming proper 
conjugation and purification (Figure 5A).  Cell culture slides were then coated with the 
0.2% Gelatin/Alexa Fluor 588 conjugate and B16F10/Vector and B16F10/GPR4 tumor 
cells were plated on top of the slides and allowed ample time to attach, enter the cell 
cycle, and degrade the conjugated gelatin.  Fluorescent microscopy was used to image the 
degradation, and analysis was performed by determining the percentage of cells that 
showed conjugated gelatin degradation, and by measuring the area of degradation.  It was 
then determined that GPR4 overexpression and activation by acidosis significantly 
inhibited the ability for B16F10 degradation.  B16F10/GPR4 cells showed a decrease in 
both the number of cells exhibiting degradation and area of degradation at an acidic pH in 
comparison to B16F10/GPR4 cells at a pH 7.9 and B16F10/Vector cells at all pH 
(Figures 5B and 5C).  This phenotype could be due to a decrease in the secretion of 
proteases by activated and overexpressed GPR4 in tumor cells. This aspect will be 
investigated in future studies. 
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Figure 5.  B16F10 Degradation Assay.  (A)  Gel electrophoresis of the 0.2% 
Gelatin/AlexaFluor 555 conjugate.  0.2% Gelatin protein was conjugated with 
AlexaFluor 555.  0.2% Gelatin and the conjugate were then stained and gel 
electrophoresis performed.  Images were analyzed under both white light and UV 
fluorescence.  (B)  Percentage of B16F10 cells showing degradation. B16F10/Vector or 
B16F10/GPR4 cells were plated on 0.2% gelatin/AlexuaFluor 555 coated cell culture 
slides, treated with pH buffered growth media, and allowed 28 hours to attach and enter 
the cell cycle.  Images were then analyzed using fluorescent microscopy and the 
percentage of cells showing degradation determined.  (C)  Average area of degraded 
regions.  The area of degraded regions corresponding to live cells was measured using 
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ImageJ imaging software. (D)  Images of B16F10/Vector degradation assay at varying 
pH.  Photos of the B16F10 cells were taken through a 10x objective using both white 
light and fluorescence. (E)  Images of B16F10/GPR4 degradation assay at varying pH.  
Photos of the B16F10 cells were taken through a 10x objective using both white light and 
fluorescence.  These results are the average of four independent experiments.  *P<0.05, 
**P<0.01 and ***P<0.001, compared to Vector cells at each pH. 
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GPR4 Activation Inhibits the Ability for Invasion through an Endothelial Cell Monolayer 
 
 To further investigate the effect of acidosis activation of GPR4 on invasion, a 
layer of HUVEC endothelial cells was allowed to form a confluent monolayer on the top 
of the transwell filters.  This assay mimicked another integral step in tumor cell 
metastasis, the ability for cells to extravasate and intravasate through a layer of 
endothelial cells.  As blood and lymph vessels are composed of endothelial cells, this 
assay resembles tumor cell invasion into and out of the blood stream.  Tumor cells were 
allowed to migrate from pH buffered migration media, through the layer of HUVEC 
endothelial cells and the transwell filter, towards NIH3T3 conditioned media.  As 
expected, the invasive ability of GPR4 overexpressing tumor cells was greatly inhibited 
upon overexpression and acidosis activation when compared to vector overexpressing 
cells of the same pH.  (Figures 6A and 6B).   
GPR4 Activation Increases Claudin-1 Expression in HUVEC Cells 
 As data indicated there was a strong inhibition in the ability of GPR4 
overexpressing tumor cells to invade through a HUVEC endothelial cell monolayer at an 
acidic pH, it was next important to deduce a possible molecular mechanism by which 
HUVEC cells could contribute to the acquired phenotype. Microarray data revealed an 
upregulation of the integral tight junction protein Claudin-1 in GPR4 overexpressing 
HUVEC cells at an acidic pH, and it was thought that an upregulation in the levels of 
Claudin-1 by endogenous mGPR4 could result in the observed inhibitory phenotype. 
Figure 7 depicts western blot confirmation of this hypothesis as it was seen that upon 
treatment of HUVEC/Vector cells with acidosis there was a noticeable increase in 
Claudin-1 levels in the HUVEC/Vector cells when compared to cells treated with a basic 
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Figure 6:  Tumor Cell Invasion Through a HUVEC Endothelial Cell Monolayer.  
(A)  B16F10 invasion through a HUVEC endothelial cell monolayer.  1x10
5
 
HUVEC/Vector cells were plated on top of an 8 m transwell filter and allowed 24 hours 
to attach and proliferate. 1x10
5
 B16F10/Vector or B16F10/GPR4 cells, resuspended in 
pH buffered migration media, were then applied to the top of the endothelial cell 
monolayer and allowed 20 hours to invade through towards pH buffered NIH3T3 
conditioned media.  Migrated cells were then stained and counted using a 10x objective.  
Three fields were counted for each transwell filter.  These results are the average of two 
independent experiments. (B)  TRAMP-C1 invasion through a HUVEC endothelial cell 
monolayer.  1x10
5
 HUVEC/Vector cells were plated on top of an 8 m transwell filter and 
allowed 24 hours to attach and proliferate. 1x10
5
 TRAMP-C1/Vector or TRAMP-
C1/GPR4 cells, resuspended in pH buffered migration media, were then applied to the 
top of the endothelial cell monolayer and allowed 16 hours to invade through towards pH 
buffered NIH3T3 conditioned media.  Migrated cells were then stained and counted using 
a 10x objective.  Three fields were counted for each transwell filter.  These results are the 
average of two independent experiments.  *P<0.05, **P<0.01 and ***P<0.001, compared 
to Vector cells at each pH. 
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or neutral pH. 
GPR4 Inhibits the Pulmonary Metastasis of B16F10 Cells 
 Up to this point, the phenotype of inhibited migration, invasion and motility upon 
acidosis activation of GPR4 has been well characterized.  To continue characterizing the 
effects of GPR4 on tumor cell motility and metastasis, it was next important to analyze 
how GPR4 affects in vivo metastasis.  A pulmonary melanoma metastasis model was 
adopted to observe the ability of B16F10/GPR4 cells to metastasize to a distant location 
in comparison to B16F10/Vector cells.  Using syngeneic C57BL/6 wild type mice as our 
murine model, tail vein injections of the aforementioned tumor cells were performed and 
the occurrence of pulmonary tumor nodules analyzed.  It was found that B16F10/Vector 
cells show a high rate of pulmonary metastasis, while B16F10/GPR4 cells showed strong 
inhibition of pulmonary metastasis (Figure 8A).  Close to 80% inhibition of pulmonary 
metastasis was observed in B16F10/GPR4 cells in comparison to B16F10/Vector cells 
(Figure 8B). 
GPR4 Overexpression Slightly Inhibits the Rate of B16F10 Primary Tumor Formation  
 To further investigate the in vivo effects of overexpressing GPR4, a subcutaneous 
melanoma injection assay was carried out to observe any differences in the rate of 
primary tumor formation between B16F10/Vector and B16F10/GPR4 cells.  As opposed 
to observing distant metastasis, this assay offered a means to observe differences in the 
growth rate and final mass of primary tumors arising from the subcutaneous injection of 
B16F10/Vector and B16F10/GPR4 cells in a C57BL/6 murine model.  A trend was 
observed in that the rate of primary tumor formation and subsequent final tumor mass 
(Figure 9A and B), was slightly inhibited upon overexpressing GPR4.  This trend,  
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Figure 7.  Western Blot Analysis of Claudin-1 Expression in HUVEC Cells at 
Varying pH.  HUVEC/Vector cells were treated with pH buffered growth media 
overnight.  Western blot analysis was then performed to detect Claudin-1 protein 
expression.  This image is representative of two independent experiments. 
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Figure 8.  B16F10 Pulmonary Metastasis in vivo Assay.  (A)  Photos of lungs from 
pulmonary melanoma metastasis of B16F10 cells. 2x10
5
 B16F10 cells were injected 
intravenously through the tail vein of C57BL/6 wildtype female mice.  Cells were 
allowed 16 days to metastasize at which point the lungs were dissected out, fixed, and 
pulmonary tumor nodules counted. (B)  Quantitative data from the pulmonary melanoma 
metastasis of B16F10/Vector and B16F10/GPR4 cells assay.  Thirteen mice were injected 
with B16F10/Vector cells, and eight mice were injected with B16F10/GPR4 cells. 
**P<0.01, compared to Vector cells. 
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however, was not statistically significant as the P value was greater than 0.05. 
GPR4 Activation Slightly Reduces Cell Proliferation 
With the rate of B16F10 primary tumor formation being slightly reduced upon 
overexpression of GPR4, it was next important to analyze differences in cell viability and 
proliferation.  B16F10/Vector and B16F10/GPR4 cells were treated with varying pH for 
up to 2 days, and an MTT assay was used to quantify live cells in the culture. There was a 
slight, non significant inhibition of cell proliferation upon acidosis activation of 
overexpressed GPR4 in B16F10 cells, as indicated by the MTT ratio depicted in Figure 
10. 
GPR4 Activation Induces Actin Stress Fiber Formation 
 With both in vitro and in vivo assays indicating an inhibition of tumor cell 
migration and metastasis upon overexpression and activation of GPR4, it was next 
important to begin deducing the molecular mechanism that could contribute, at least 
partially, to the observed phenotype.  The activation of the small GTPase Rho results in 
the formation of actin stress fibers, which are known to play a role in cell motility.  As 
the OGR1 family of G protein coupled receptors, inclusive of GPR4, is known to activate 
the G12/13/Rho pathway under certain stimuli, it was thought to analyze the occurrence of 
actin stress fiber, indicative of the pathway in question (28).  Figure 11 visualizes the 
high occurrence of stress fiber formation upon acidosis activation of B16F10/GPR4 cells 
in comparison to cells treated with a basic or neutral pH.  Furthermore, treatment of 
B16F10/GPR4 cells with CN01, a known cell permeable Rho activator, showed 
similarities in the rate of stress fiber formation when compared to B16F10/GPR4 cells 
activated by an acidic pH.  Although this assay is not a direct quantification of activated 
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Figure 9.  B16F10 Subcutaneous Melanoma Injection.  (A)  Photos of B16F10 
subcutaneous melanoma injection.  2x10
5
 B16F10/Vector and B16F10/GPR4 cells were 
injected subcutaneously on the hip flank of C57BL/6 wildtype female mice.  Cells were 
allowed 14 days to form primary tumors, with the length, width and height of the tumors 
being measured every four days. After 14 days the tumor were dissected and weighed.  
(B)  Quantitative data from B16F10 subcutaneous melanoma injection.  11 mice were 
injected with B16F10/Vector cells, and 11 with B16F10/GPR4 cells.  P=0.32. 
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Figure 10.  MTT Assay of B16F10 Cells at Varying pH.  An MTT assay was 
performed for two days on B16F10/Vector and B16F10/GPR4 cells.  This data is the 
average of five independent experiments. 
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levels of Rho, it offers an indirect means of observing how pH and CN01 may influence 
the levels of activated Rho as visualized through the occurrence of actin stress fibers. 
CN01 Inhibits B16F10 Cell Motility  
As it has been reported [28] and confirmed by actin staining (Figure 11) that 
GPR4 activation by acidosis increases the levels of activated RhoA, it was thought that 
this change in the cytoskeletal phenotype could contribute to the inhibition of motility 
and metastasis observed upon GPR4 activation in tumor cells.  To test this hypothesis, 
B16F10/Vector cells were treated with the known cell permeable RhoA activator CN01 
(Calpeptin) and the effect of Rho activation on directional motility observed using a 
wound closure assay.  It was found that treatment with 0.5unit/mL CN01 inhibited the 
ability of B16F10/Vector cells for wound closure (Figure 12A).  This phenotype was 
significant at all pH tested in comparison to B16F10/Vector cells treated with 2.5 L/mL 
of DMSO, the solvent  for CN01 (Figure 12B). 
CN01 Inhibits Pulmonary Metastasis of B16F10/Vector Cells 
 After determining that Rho activation by CN01 inhibits the ability for 
B16F10/Vector cells for directional motility, it was next important to determine if Rho 
activation affected the ability for B16F10/Vector cell pulmonary metastasis.  
B16F10/Vector cells were pretreated for two hours with either 0.5unit/mL CN01 or 
2.5 L/mL DMSO, and 2x10
5
 tumor cells were injected in the tail vein of C57BL/6 wild 
type female mice and allowed 16 days to metastasize.  There was significant inhibition in 
the rate of B16F10/Vector pulmonary metastasis after treatment of cells with CN01 when 
compared to cells treated with DMSO, indicating that this treatment inhibits 
B16F10/Vector metastasis in vivo (Figure 13). 
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Figure 11.  B16F10 Actin Staining Upon Treatment at Varying pH. B16F10 cells 
were serum starved for three days then treated with pH buffered serum free media or 
serum free media with CN01.  Cells were then fixed, permealized and stained with 
Rhodamine Phalloidin.  Pictures were then taken using a fluorescent microscope.  Images 
are representative of three independent experiments. 
 
 
 
 
 
 
 
 
 
 
 
   50 
 
 
Figure 12.  B16F10 Wound Closure at Varying pH and Upon Treatment with CN01.  
(A)  Photos of B16F10/Vector cell wound closure after treatment with CN01.  
B16F10/Vector cells were allowed to grow to confluency at which point a wound was 
created and the cells treated with either 0.5unit/mL CN01 or 2.5 L/mL DMSO in growth 
media buffered to varying pH.  Photos were taken at 0 and 16 hours.  (B)  Quantification 
of B16F10/Vector cell wound closure after treatment with CN01.  The wounds were 
measured at 0 and 16 hours and the distance cells traveled determined.  These results are 
the average of two independent experiments.  *P<0.05, **P<0.01, in comparison to cells 
treated with DMSO at the same pH. 
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Figure 13.  B16F10/Vector Pulmonary Metastasis Assay After Treatment with 
CN01.  (A)  Photos of B16F10/Vector cell pulmonary metastasis after treatment with 
CN01.  B16F10/Vector cells were treated for two hours with either 0.5unit/mL CN01 or 
2.5 L/mL DMSO in growth media.  2x10
5 
cells were then injected into female C57BL/6 
wild type mice via the tail vein.  Cells were allowed 16 days to metastasize at which point 
the lungs were dissected, fixed and analyzed.  (B)  Quantification of B16F10/Vector cell 
pulmonary metastasis after treatment with CN01.  The number of pulmonary tumor 
nodules was counted using a dissecting microscope.  Seven mice were injected with 
B16F10/Vector-DMSO cells, and seven with B16F10/Vector-CN01 cells.  *P<0.05, in 
comparison to DMSO treated cells. 
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CN01 Slightly Increases the Rate of Primary Tumor Formation 
To continue with the in vivo analysis of the effect of Rho activation on 
B16F10/Vector cells, a subcutaneous melanoma injection assay was utilized to determine 
the rate of primary tumor formation. B16F10/Vector cells treated for two hours with 
either 0.5unit/mL CN01 or 2.5 L/mL DMSO and 2x10
5
 cells were injected 
subcutaneously on the hip flank of female C57BL/6 wild type mice.  It was observed that 
CN01 slightly increases the rate of B16F10/Vector cell primary tumor formation in 
comparison to cells treated with DMSO, however these results were not statistically 
significant (Figure 14). 
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Figure 14. B16F10/Vector Subcutaneous Melanoma Injection After Treatment with 
CN01.  (A)  Primary tumors from the B16F10/Vector subcutaneous melanoma injection 
after treatment with CN01.  2x10
5
 B16F10/Vector and B16F10/GPR4 cells were injected 
subcutaneously on the hip flank of C57BL/6 female mice.  Cells were allowed 14 days to 
form primary tumors, with the length, width and height of the tumors being measured 
every four days.  After 14 days the tumor were dissected and weighed.  (B) Primary 
tumors from the B16F10/Vector subcutaneous melanoma injection after treatment with 
CN01.  Eight and nine mice were injected with B16F10/Vector cells treated with DMSO 
and CN01, respectively. P=0.42. 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4:  Discussion 
The acquisition of a motile and metastatic phenotype is one of the most 
devastating properties developed by many types of cancerous cells, often resulting in a 
severely worsened prognosis.  Traditionally and historically cancer has been treated via 
the excision of the primary tumor by surgery or direct radiation, with this procedure 
adequate at eradicating localized cancerous tissue [12, 21].  However, upon 
metastasizing, strategies for combating the cancer become less efficient.  These 
treatments often result in non-specific cell death and eradication, bringing about 
widespread tissue damage and a decrease in patient quality of life.   Rather than complete 
eradication of cancerous tissue, the final result is often only an extension of patient 
survival [21, 51].  It is therefore of the upmost importance to develop novel strategies to 
combat cancer metastasis.  Drugs and therapies designed to prevent the initial acquisition 
of an invasive phenotype would greatly increase the life expectancy and prognosis of 
many types of cancer.  As cell metastasis is a very complex and involved process, there 
exists the potential for numerous opportunities to inhibit the ability for cells to 
metastasize.  From an inability to detach from the primary tumor, to a decrease in 
viability in the lymph and vascular systems or inhibition of the ability to arrest, 
extravasate and colonize, the beneficial implications of strategically targeting the 
pathways involved in metastasis are blatant and widespread.  
Recent years have seen the tumor microenvironment present numerous novel 
targets for the development of new cancer fighting strategies.  From cell autonomous to 
inclusive of the tumor microenvironment, the current view of cancer not only 
incorporates the cancerous cells found within the primary tumor, but also the various 
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cells, tissues and factors present in the immediate environment that help dictate tumor 
progression [3].  It is now known that the tumor microenvironment can influence many 
different aspects of the progression of the cancer, inclusive of its ability for metastasis 
[12].  Many characteristics of the tumor microenvironment present evolutionary 
constraints on tumor cells.  Tumor cells resistant to certain harsh microenvironmental 
conditions are often left with a highly invasive and progressive phenotype, as Darwinian 
evolution dictates a model of survival of the fittest [12, 17].  The hallmarks of the tumor 
microenvironment that have been found to actively select for advanced tumor cells are 
hypoxia, acidosis and high interstitial fluid pressure [14, 17]. 
Acidosis is a well-defined characteristic of the tumor microenvironment.  Thought 
to arise due to alterations in metabolism and glycolysis, acidosis not only selects for 
invasive and progressive cancer cells, but also induces cell death in neighboring, non-
tumorigenic cells, in turn facilitating the tumor cell’s expansion and invasion into the 
newly created niche [19, 20, 23].  These conditions make microenvironmental acidosis an 
interesting topic of research.    A potential for drug discovery lies in development of 
means to combat the ability for tumor cells to exist in a viable and tumorigenic state 
within microenvironmental acidosis.  Furthermore, it is possible to capitalize on the 
existence of acidosis by delineating molecular pathways which inhibit the ability of 
tumor cells for proliferation and metastasis in response to acidosis. 
The incredible diversity of the GPCR family of receptors leaves them as the target 
for the majority of therapeutic agents [25, 28].  As the largest family of cell surface 
receptors, GPCRs are responsible for directing an array of cellular functions, from 
endocrine activity, to immune responses, to regulating cell proliferation [24, 25].  
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Furthermore, GPCRs are found in a large number of tumor cells, implicating a function in 
certain processes of tumorigenesis [27].  Their function in tumorigenesis, however, is not 
well defined.  Recently, a family of proton sensing G-protein coupled receptors has been 
identified that are activated by extracellular protons [29, 30].  As microenvironmental 
acidosis is due to the accumulation of extracellular protons, this family of receptors, and 
their subsequent downstream pathways, may be the target for novel and realistic 
therapeutic strategies. 
GPR4, a member of the aforementioned family of proton sensing GPCRs, has 
been shown to be fully activated at an acidic pH.  Furthermore, this activation results in 
the initiation of numerous signaling pathways, some of which may be directly involved in 
cell motility and metastasis.  Specifically, acidosis activation of GPR4 induces activation 
of the G12/13/Rho signalling pathway, a pathway responsible for actin reorganization, an 
important process in cell motility [29, 30, 46].  Activation of the G12/13/Rho pathway by 
GPCRs has been shown to result in an inhibition of cell motility and migration in some 
cell systems [36, 47].  Furthermore, GPR4 has been shown to couple to the Gs pathway, 
which results in the activation of the cAMP pathway.  Exchange proteins activated by 
cAMP (EPAC) overexpression has been shown to increase the invasive ability of 
melanoma cells, implying that the Gs pathway, like the G12/13, may play a roll in 
migration and invasion [52].  cAMP/PKA signaling is also reported to influence cell 
migration and cytoskeletal rearrangement as some important steps in cell motility and 
metastasis, like Cdc42 and Rac activation, require the influence of the cAMP/PKA 
signaling pathway [53].  The Gq pathway has also been reported to play a role in motility 
regulation [47].   Although the activation of GPR4 by acidosis has been well defined, 
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there exists very little indication of how the activation will influence the ability for tumor 
cells to acquire a motile and metastatic phenotype.  With GPR4 activation having been 
previously reported to activate signaling pathways directly involved in cell motility, and 
G-protein coupled receptors being the target of the majority of therapeutics, GPR4 
provides an excellent target for the development of novel anti-cancer therapies. 
B16F10 melanoma and TRAMP-C1 prostate cancer cells offer a good model for 
the characterization of the effect of GPR4 overexpression and activation on tumor cell 
motility and metastasis.  As both cell types express low levels of endogenous mouse 
GPR4 (Figure 1), the overexpression of huGPR4 should clearly highlight the effects, if 
any, of GPR4 activation on cellular processes.  In fact, overexpression of huGPR4 was 
successful in both B16F10 and TRAMP-C1 cell lines, as can be observed in Figure 1.  As 
both B16F10 and TRAMP-C1 cell lines are highly motile, overexpression of huGPR4 left 
us with a working model in which to analyze the effects of GPR4 activation on tumor cell 
motility. 
In concordance with previous results, our series of in vitro cell motility (Figure 2), 
migration (Figure 3) and invasion (Figures 4 and 6) assays, along with our actin stress 
fiber assay (Figure 12), confirmed that GPR4 is fully activated at an acidic pH [29].  
While this data clearly highlights that GPR4 is activated at an acidic pH, it also confers 
that GPR4 activation has an effect on tumor cell motility.  We observed that 
overexpression and full activation of GPR4 at an acidic pH results in a strong inhibition 
of cell motility.  Furthermore, it appears that acidosis activation of GPR4 increases the 
occurrence of actin stress fibers, indicating an upregulation of activated GTP bound Rho 
as facilitated by the G12/13/Rho signaling pathway.  Although the formation of actin stress 
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fibers is indicative of Rho activation, actin stress fiber staining only offers an indirect 
means of analyzing the levels of activated Rho. 
Figure 2 depicts the results of numerous wound closure assays performed on 
B16F10 and TRAMP-C1 cells.  Wound closure assays are used to analyze differences in 
directional, spontaneous motility, and it was seen that GPR4 overexpression and 
activation inhibits the ability for tumor cells to close the wound.  As GPR4 activation 
upregulates the Rho pathway, it was thought to treat vector overexpressing B16F10 cells 
with CN01, a chemical containing the known cell permeable Rho activator calpeptin.  In 
fact, treatment with CN01 inhibited the ability for B16F10/Vector cells to close the 
wound (Figure 13), indicating that Rho activation may be responsible for the phenotype 
of motility inhibition. 
Previous studies have shown that a delicate regulation of Rho activation is critical 
for cell migration.  In some cases, studies have indicated that an increase in the levels of 
Rho-GTP actually increase cell motility and metastasis [44].  Others, however, have 
reported that upregulation of Rho-GTP acts to inhibit cell motility [36, 47].  It seems the 
most plausible explanation for the contradictory results is the necessity for tight 
regulation in the levels of activated Rho, as steps and processes involved in motility 
require an upregulation of Rho-GTP, and others a downregulation. 
Mesenchymal motility, defined by elongated and polarized cell morphology, is 
characteristic of B16F10 cells [45].  This form of motility requires differing levels of Rho 
at different stages in the process [45].  During mesenchymal motility, Rac1 and Cdc42, 
members of the Rho family of GTPases, are responsible for cell polarization and 
directionality, respectively.  RhoA and its effecter ROCK, however, need to be reduced 
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to extend protrusions at the front of the cell [36, 39, 45].  This is a crucial step in 
mesenchymal motility as it enables the formation of new, focal adhesion complexes, 
along with the subsequent “pulling” of the cell forward [36, 39].  Furthermore, Rho is 
involved in the occurrence of focal adhesion complexes, as its activation is needed to 
form them, and its inactivation necessary for the process of focal adhesion turnover, 
which propels the cell forward [36, 46].  These facts, therefore, could account for the 
observed motility inhibition of the highly motile B16F10/Vector cells upon treatment 
with CN01 (Figure 12).  By constituently activating Rho, CN01 may induce the 
occurrence of focal adhesion complexes, inhibit protrusions at the leading edge of the 
cell, and decrease the ability for focal adhesion turnover.  These effects would certainly 
culminate in the observed inhibition of motility found upon CN01 activation of Rho in 
B16F10/Vector cells. 
We further characterized the effects of GPR4 activation on tumor cell motility by 
examining chemotaxis as revealed by transwell assays.  Chemotaxis is a form of 
directional migration in which cells respond to different chemokines and signals to 
migrate along a chemical gradient.  By isolating NIH3T3 cell-conditioned media, we 
were able to mimic an aspect of the tumor microenvironment as fibroblasts are found in 
the connective tissue and extra cellular matrix surrounding the tumor [12].  Therefore, by 
applying it to the bottom of a transwell migration chamber, we were able to analyze how 
cells responded to the chemical gradient created between the migration media and the 
NIH3T3 chemoattractant.  It was seen that B16F10 and TRAMP-C1 cells responded well 
to the factors secreted by the NIH3T3 fibroblasts as this chemoattractant induced high 
levels of directional migration in B16F10 and TRAMP-C1 vector overexpressing cells, as 
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well as GPR4 overexpressing tumor cells at a basic pH.  However, upon full activation of 
GPR4 by acidosis, there was a significant inhibition of the GPR4 overexpressing tumor 
cells to migrate towards the chemoattractant.  Therefore, GPR4 overexpression and 
subsequent activation not only inhibit the motility of tumor cells, but also their ability to 
respond to and migrate towards a chemoattractant (Figure 3). 
Invasion through the extra cellular matrix is an import step in the initiation of 
tumor cell metastasis.  This process requires the degradation of the extra cellular matrix, 
often by matrix metalloproteinases, and the subsequent movement of the tumor cell 
through this newly vacant space.  Matrigel is used to resemble the ECM in vitro, with the 
ability for cells to invade through it being indicative of their ability to move through the 
actual ECM.  We found that GPR4 overexpression and activation greatly reduced the 
ability for B16F10 and TRAMP-C1 tumor cells to invade through matrigel, and thus the 
ECM (Figure 4).  The observed phenotype of motility inhibition upon GPR4 activation 
could be due to an arrest of cells in the ECM, a decrease in the motility of cells through 
the ECM, a decrease in the cells ability to respond to the chemoattractant, decrease in the 
ability of the tumor cells to degrade the ECM, or a combination of any and all of these 
contributors.  It was in fact found that GPR4 activation and overexpression inhibited the 
ability of B16F10 cells to degrade gelatin (Figure 5).  Although we report that activation 
of GPR4 by acidosis inhibits the ability for degradation of the extra cellular matrix, other 
studies have indicated that specific microenvironmental conditions increase the 
invasiveness of tumor cells.   Hypoxia has been reported to increase the secretion of 
matrix metalloproteinases (MMP-2 and MMP-9) in pancreatic, colorectal and breast 
tumor cells, a characteristic that could be attributed to hypoxia induced acidosis [54].  
   61 
 
Moellering et al. reported that acidosis treatment of melanoma cells resulted in the 
acquisition of a more invasive and motile phenotype, with other reports indicating the 
same phenotype and attributing it to change in gelatinase activity [55, 56].    However, 
this phenotype was clearly not replicated in our B16F10/Vector and B16F10/GPR4 cell 
lines using the gelatin degradation assay, and this trend could be attributed to differences 
between tumor cell lines or different assays.  It has been shown that different members of 
the MMP family can exhibit different and contradictory roles in tumor cell progression, 
with individual MMPs often contradicting their own function at different stages in tumor 
cell progression.  Overall, however, MT1-MMP, MMP-2 and MMP-9 have been reported 
to be proteolytic activating, resulting in the degradation of immediate physical barriers 
and subsequent migration and invasion [57].  Therefore, it is possible that GPR4 
activation results in a decrease of pro-invasive MMPs.    The observed inability for 
activated GPR4 overexpressing tumor cells to degrade the ECM may play a role in the 
observed inhibition of invasion, with this phenotype potentially being due to a reduction 
in specific MMPs.  The potential role of GPR4 in regulating protease expression or 
activity warrants further investigation.  Although in many aspects acidosis, and the 
subsequent evolution of tumor cells to resist acidosis, increases the invasive and 
metastatic phenotype of tumor cells, it is possible that GPR4, with its unique ability to 
respond to and become activated by extracellular protons, presents a novel means to 
inhibit metastasis and invasion in response to acidosis.  
As intravasation and extravasation through endothelial cells is a crucial aspect in 
the ability of cells to metastasize, we analyzed the influence, if any, GPR4 
overexpression and activation had on the ability for tumor cells to invade through a 
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HUVEC endothelial cell monolayer.  This assay is important as it highlights a step of 
metastasis that enables tumor cells to travel through the blood stream and colonize in 
distant locations.  As expected, GPR4 activation in tumor cells reduced their ability to 
invade through the endothelial cell monolayer (Figure 6).  The culmination of huGPR4 
activation in tumor cells and possible endogenous mGPR4 activation in endothelial cells 
resulted in a very strong inhibition of invasion.  This phenotype could arise due to the 
fact that GPR4 activation activates the GTPase Rho, whose activation is correlated with 
an increase in focal adhesion complexes.  Therefore, tumor cells overexpressing activated 
GPR4 may bind very strongly with the endothelial cells found in the monolayer, 
especially if GPR4 activation in endothelial cells causes an increase in cell-cell cadherins.  
Furthermore, analysis of microarray data indicated that acidosis activation of GPR4 in 
HUVEC cells increased the expression of Claudin-1, a tight junction protein.  With this 
data confirmed by western blot analysis (Figure 7), it is possible that Claudin-1 could 
contribute to the observed phenotype of motility inhibition, with an increase in tight 
junctions decreasing the permeability of the endothelial cell monolayer.  
After fully characterizing the effects of acidosis activation of GPR4 on in vitro 
tumor cell motility, migration and invasion, it was necessary to utilize in vivo models for 
examining metastasis and primary tumor formation.  Using tail vein injections on mice, it 
was found that GPR4 overexpression greatly reduced the pulmonary metastasis of 
B16F10 cells (Figure 8).  This phenotype is the culmination of those observed during the 
in vitro assays, with in vivo metastasis incorporating many of the mechanisms tested in 
vitro, from migration, to invasion through the extra cellular matrix, to invasion through 
an endothelial cell monolayer.  It must be noted, however, that cells were not treated with 
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an acidic pH prior to injection.  Therefore, it appears the physiological pH sufficiently 
activates GPR4 to result in the metastasis inhibitory phenotype.  Although full activation 
of GPR4 is found between a pH of 6.8-6.4, reports have indicated significant activation 
between a pH of 7.4 and 7.0, and we have seen a decrease in in vitro motility and 
migration at a physiological pH.  It therefore appears the lower levels of activation found 
at a physiological pH is sufficient at inhibiting the in vivo metastasis of GPR4 
overexpressing B16F10 cells.  As it is thought that Rho is involved in the observed 
inhibition of motility upon acidosis activation of GPR4 in vitro, we hypothesized that 
activating Rho in the highly metastatic B16F10/Vector cells would decrease their ability 
for pulmonary metastasis.  This hypothesis was confirmed as pretreating B16F10/Vector 
cells with CN01 prior to injection greatly reduced the cell’s ability for metastasis (Figure 
13).  As previously stated, Rho activation increases cell-cell adhesion, so it is possible 
cells became arrested in the mouse vasculature before being able to colonize in the lungs.  
Constitutive activation of Rho also decreases the ability for cells to extend protrusions 
which results in an inhibition of mesenchymal motility, another potential explanation for 
the observed phenotype in vivo.  
Although GPR4 overexpression resulted in a profound effect on in vivo tumor cell 
metastasis, it resulted in no significant difference between the rate of in vivo B16F10 
primary tumor formation or in vitro B16F10 cell proliferation (Figures 9 and  10, 
respectively).  While there is a noticeable trend of GPR4 overexpression slightly 
decreasing the rate of primary tumor formation, this result is not statistically significant 
and it is consistent with those results obtained with the MTT assay.  Furthermore, Rho 
activation by CN01 seems to slightly increase the rate of primary tumor formation of 
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B16F10/Vector cells in comparison to those treated with DMSO as a control (Figure 14).  
This observation, however, is not statistically significant, and could be attributed to an 
increase in adhesion and interaction with the extra cellular matrix and surrounding cells.  
Rho proteins are involved in a variety of tumorogenic processes, inclusive of cell cycle 
progression, an evasion of apopotisis, cytoskeletal rearrangement, interaction with 
surrounding fibroblasts, and degradation of the ECM [58].  Therefore, if Rho activation 
stimulates adhesion and interactions within the extra cellular matrix, it is possible that 
B16F10/Vector cells will have an increased ability for primary tumor formation after 
treatment with CN01. 
The results characterized in this thesis have important implications in tumor cell 
biology.  These results offer a novel means of inhibiting tumor cell motility and 
metastasis, that being through activation of GPR4 by acidosis or small molecules.  This is 
an exciting finding as GPCRs are widely used as therapeutic targets.  In terms of 
developing therapeutic applications from these findings, a potential lies in the 
development of an agonist that successfully and fully activates endogenous levels of 
GPR4 in human primary tumors, in turn offering a means of inhibiting the acquisition of 
a metastatic phenotype.  Furthermore, upon fully deducing the molecular mechanisms by 
which GPR4 inhibits motility and metastasis, it may be possible to develop a drug which 
utilizes the same mechanisms to prevent metastasis in human patients.  Future directions 
for this project include the full characterization of the molecular pathway responsible for 
the observed inhibition of motility and migration.  In addition to determining the exact 
mechanism by which the activation of Rho seemingly plays a part in the observed 
motility and metastasis inhibition, it will be important to characterize differences in the 
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occurrence of focal adhesion complexes, the rate of focal adhesion turnover, trends in the 
epithelial-mesenchymal transition between different cell types, and differences in the 
secretion of proteases responsible for extra cellular matrix degradation.  Although there is 
much to be learned in the future, the findings in this thesis present a strong starting point 
towards the development of a novel anti-metastasis therapy that capitalizes on the 
observed effects of motility and metastasis inhibition upon overexpression and acidosis 
activation of GPR4.   
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